Hansoh Pharmaceutical Group Co (HKSE:03692) Debt-to-Equity

: 0.19 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

Hansoh Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$4,900 Mil. Hansoh Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$81 Mil. Hansoh Pharmaceutical Group Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$26,443 Mil. Hansoh Pharmaceutical Group Co's debt to equity for the quarter that ended in Jun. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Debt-to-Equity or its related term are showing as below:

HKSE:03692' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.19 Max: 0.21
Current: 0.17

During the past 8 years, the highest Debt-to-Equity Ratio of Hansoh Pharmaceutical Group Co was 0.21. The lowest was 0.00. And the median was 0.19.

HKSE:03692's Debt-to-Equity is ranked better than
63.63% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs HKSE:03692: 0.17

Hansoh Pharmaceutical Group Co Debt-to-Equity Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

0.19

0.17

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity										0.19	0.20	0.19	0.19	0.17

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansoh Pharmaceutical Group Co Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Debt-to-Equity falls into.

Hansoh Pharmaceutical Group Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hansoh Pharmaceutical Group Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.357	+	4871.459)	/	25290.176
	=	0.19

Hansoh Pharmaceutical Group Co's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4900.442	+	81.037)	/	26442.832
	=	0.19

Hansoh Pharmaceutical Group Co (HKSE:03692) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hansoh Pharmaceutical Group Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Debt-to-Equity

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines